|
|
Volumn 58, Issue 3, 2010, Pages 466-
|
|
Re: Overall survival analysis of a phase II randomized controlled trial of a poxviral-based psa-targeted immunotherapy in metastatic castration-resistant prostate cancer
a
a
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CANCER VACCINE;
PROSTATE SPECIFIC ANTIGEN TARGETED POXVIRAL VACCINE;
PROVENGE;
UNCLASSIFIED DRUG;
ANTIBODY TITER;
BONE METASTASIS;
CANCER SURGERY;
CANCER SURVIVAL;
CLINICAL TRIAL;
HUMAN;
LYMPH NODE METASTASIS;
METASTATIC CASTRATION RESISTANT PROSTATE CANCER;
NOTE;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
PROSTATE CANCER;
PROSTATECTOMY;
SOLID TUMOR;
|
|
EID: 77955497798
PISSN: 03022838
EISSN: None
Source Type: Journal
DOI: 10.1016/j.eururo.2010.06.020 Document Type: Note |
|
Times cited : (2)
|
|
References (1)
|
